Highlights:
- Hemostemix has resolved all pending lawsuits, reached a settlement with Aspire Health Services, and recovered legal ownership of all of its intellectual property. This includes the randomized tables required to analyze the data from the HS 12-01 Phase II clinical trial, the data from the ACP-01 clinical trial in North America and South Africa, and all of the historical Hemostemix Israel data.
- Hemostemix Inc. lately announced a non-brokered private placement of up to 15 million units priced in line with the market to its existing shareholders.
- The Company recently announced that PreCerv Inc. ("PreCerv'') has been incorporated as an entirely owned subsidiary. Hemostemix will grant PreCerv a global field of use licence for NCP-01 and its autologous stem cell technology to treat central and peripheral nervous system diseases
- Hemostemix reported the conclusion of the first tranche of its $690,388.80 gross proceeds non-brokered private offering of units announced on May 19, 2022. A total of 2,301,296 units were issued as part of the offering, each of which cost $0.30.
Hemostemix Inc is a clinical stage biotechnology based company. The company's objective includes developing, manufacturing, and marketing blood-derived cell treatments for various medical problems. Its technical platform for generating autologous cell treatments is geared toward vascular disease treatment.
Hemostemix has generated and published seven peer-reviewed studies about the safety and efficacy of their principal product ACP-01, also have been the recipient of the World Economic Forum Technology Pioneer Award. The company was created in 2003 and is a publicly traded autologous stem cell therapy firm. The company recently announced the closure of the first tranche of its previously announced non-brokered unit private placement.
Provisos And Exemptions of The Placement Offer
The eligibility criteria extends the offering only to existing shareholders of the Company who own common shares of the Company as of the close of business on May 16, 2022(and who continue to hold such common shares as of the closing date)
The existing shareholder exemption confines a shareholder to a highest investment of $15,000 in a period of 12 months unless the shareholder has obtained advice regarding the suitability of the investment from a person who is registered as an investment dealer in the jurisdiction, if the shareholder is a Canadian resident.
It is a non-brokered private placement with an utmost sum of 15 million units priced in the market’s viewpoint. Each Unit contains one common share in…
